The artificial lung industry is undergoing rapid transformation driven by technological advancements and rising demand for respiratory support devices. This market is witnessing substantial market growth as healthcare providers increasingly adopt innovative solutions to address chronic respiratory conditions. With ongoing advancements improving device efficiency and patient outcomes, the market is poised for significant expansion.
Market Size and Overview
The Global Artificial Lung Market size is estimated to be valued at USD 2.10 billion in 2025 and is expected to reach USD 4.12 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032.
The growing prevalence of pulmonary diseases and increasing investment in biomedical research are core factors driving this Artificial Lung Market Growth. Additionally, the expanding geriatric population and rising demand for minimally invasive devices further enhance the market scope. Market reports highlight emerging opportunities in improving oxygenation and extracorporeal membrane oxygenation (ECMO) technologies.
Market Segments
The Artificial Lung Market is segmented primarily by product type, end-user, and technology. Under product type, extracorporeal artificial lungs and implantable artificial lungs form critical sub-segments, with extracorporeal devices dominating in 2024 due to widespread clinical adoption. Implantable artificial lungs represent the fastest-growing sub-segment, driven by breakthrough biocompatibility advancements demonstrated in 2025 clinical trials.
In terms of end users, hospitals and specialized respiratory care centers remain dominant, whereas home healthcare is a burgeoning sub-segment fueled by telemedicine integration. Technology-wise, membrane oxygenators continue to be prevalent, while novel hybrid membrane systems are gaining traction rapidly, supporting market trends toward enhanced patient comfort and efficacy.
Market Drivers
A significant market driver for the artificial lung industry is the surge in respiratory illnesses exacerbated by pollution and lifestyle-related factors, combined with increasing regulatory approvals of new devices. For instance, in 2024, the global adoption of advanced ECMO systems increased by 15%, reflecting enhanced clinical outcomes and improved patient management protocols. Governments in regions such as North America and Europe have introduced favorable reimbursement policies supporting innovative respiratory devices, which further bolster market revenue and business growth potential.
Segment Analysis: Product Type
Focusing on product type segments, extracorporeal artificial lungs accounted for the largest market revenue in 2024, attributed to their established clinical efficacy for acute respiratory distress syndrome (ARDS) and COVID-19-related therapies. Implantable artificial lungs, however, represent the fastest-growing sub-segment, posting a CAGR exceeding 12% between 2024 and 2025, propelled by several successful preclinical trials. Case studies from leading medical institutions validate the longer-term sustainability and improved patient mobility associated with implantable devices, signaling transformative shifts in patient care paradigms for respiratory failure.
Consumer Behaviour Insights
Recent consumer behavior trends in 2024–2025 reveal a growing preference for personalized and remote patient monitoring solutions, reflecting higher demand for customized artificial lung systems adapted to patient-specific physiological conditions. Pricing sensitivity has increased among healthcare providers, driving market dynamics towards cost-effective models supported by innovative manufacturing processes. Moreover, sustainability preferences have prompted market players to develop recyclable and biocompatible components, aligning with broader healthcare environmental goals as indicated by a 2025 industry survey where 68% of clinicians prioritized eco-friendly device options.
Key Players
Prominent market players include Medtronic plc, Getinge AB, LivaNova PLC, and Terumo Corporation, alongside a cohort of emerging innovators advancing the market landscape. In 2024-2025, Medtronic expanded production capacity for next-generation artificial lung devices in North America, achieving a 20% increase in output. Similarly, LivaNova PLC launched advanced portable ECMO systems in early 2025, significantly impacting market growth strategies and improving accessibility in emerging markets. Terumo Corporation optimized its supply chain to enhance delivery timeframes, facilitating faster adoption across key regions.
Key Winning Strategies Adopted by Key Players
Leading market companies have adopted unique strategies to maintain competitive advantage and stimulate business growth. Medtronic, in 2025, implemented AI-driven predictive maintenance in its artificial lung devices, reducing hospital downtime by 30%, a novel approach not widely seen in the sector. LivaNova’s collaboration with academic research institutions facilitated accelerated product development cycles, shortening the go-to-market timeline by 25%, thereby harnessing combined expertise for quicker innovation. Additionally, Getinge AB embraced subscription-based models for device servicing in 2024, enhancing customer retention and recurring revenue, underscoring a strategic shift from traditional sales to service-oriented growth.
---
Frequently Asked Questions (FAQs)
Q1: Who are the dominant players in the Artificial Lung Market?
Key market companies include Medtronic plc, Getinge AB, LivaNova PLC, and Terumo Corporation, each driving industry trends through continuous innovation, capacity expansion, and strategic partnerships during 2024 and 2025.
Q2: What will be the size of the Artificial Lung Market in the coming years?
The market size is projected to grow from USD 2.10 billion in 2025 to USD 4.12 billion by 2032, reflecting a robust CAGR of 10.1% fueled by technological advances and rising respiratory disease incidence.
Q3: Which end-user segment has the largest growth opportunity?
Hospitals and specialized respiratory centers form the dominant segment; however, home healthcare is rapidly emerging with significant growth potential due to increased telehealth adoption.
Q4: How will market development trends evolve over the next five years?
Market trends will focus on miniaturization, AI integration in artificial lung devices, and sustainability-driven product innovation, enhancing patient experience and improving clinical efficacy.
Q5: What is the nature of the competitive landscape and challenges in the Artificial Lung Market?
The landscape features a mix of established players and startups facing challenges such as high R&D costs, regulatory approvals, and pricing pressures; however, market opportunities related to emerging technologies and healthcare demands remain substantial.
Q6: What go-to-market strategies are commonly adopted in the Artificial Lung Market?
Innovative strategies include AI-driven device management, academic collaborations for rapid prototyping, and subscription-based servicing models, all influencing market growth and customer engagement patterns.
Get More Insights on Artificial Lung Market
Read More Articles related to this industry- Key Development in Artificial Insemination Industry
About Author-
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment